Alkem Laboratories Ltd Upgraded to Hold by MarketsMOJO on Improved Valuation and Technicals

Valuation Upgrade Signals Improved Investment Appeal

One of the primary catalysts behind the rating upgrade is the change in Alkem Laboratories’ valuation grade from fair to attractive. The company currently trades at a price-to-earnings (PE) ratio of 26.60, which, while higher than some peers, is considered reasonable given its robust return on capital employed (ROCE) of 19.13% and return on equity (ROE) of 17.61%. These returns indicate efficient capital utilisation and profitability, supporting the valuation premium.

Further valuation metrics reinforce this positive outlook. The enterprise value to EBITDA (EV/EBITDA) ratio stands at 21.99, and the price-to-book (P/B) value is 4.79, both suggesting that the stock is attractively priced relative to its asset base and earnings before interest, taxes, depreciation, and amortisation. The PEG ratio of 2.39, while slightly elevated, reflects moderate growth expectations relative to earnings, aligning with the company’s steady profit growth of 11.1% over the past year.

Compared to peers such as Lupin (PE 21.59, EV/EBITDA 14.03) and Zydus Lifesciences (PE 17.49, EV/EBITDA 11.59), Alkem’s valuation is competitive, especially considering its higher ROCE and ROE figures. This valuation upgrade from fair to attractive has been a key driver in the overall rating improvement.

Technical Indicators Shift to Mildly Bearish, Supporting Stability

The technical grade for Alkem Laboratories has improved from bearish to mildly bearish, signalling a stabilisation in price momentum. While the daily moving averages remain bearish, weekly and monthly technical indicators present a more nuanced picture. The monthly KST (Know Sure Thing) indicator has turned bullish, suggesting potential upward momentum in the medium term, although the weekly KST remains bearish.

Other technical signals such as the MACD (Moving Average Convergence Divergence) remain bearish on a weekly basis but mildly bearish monthly, indicating a possible easing of downward pressure. The RSI (Relative Strength Index) shows no clear signal on both weekly and monthly charts, while Bollinger Bands indicate sideways movement monthly and bearish trends weekly. Overall, these mixed signals justify the mildly bearish technical grade, reflecting a cautious but improving technical outlook.

Price action has been relatively stable, with the stock currently trading at ₹5,355.20, slightly down 0.90% from the previous close of ₹5,404.05. The 52-week high stands at ₹5,933.00 and the low at ₹4,716.75, indicating a moderate trading range. Short-term returns have been modest, with a 1-week gain of 0.13%, outperforming the Sensex’s slight decline of 0.04% over the same period.

Financial Trend Remains Flat but Supported by Strong Fundamentals

Despite the upgrade, Alkem Laboratories’ recent financial performance has been largely flat, particularly in the third quarter of FY25-26. Operating profit growth has been subdued, with a five-year compound annual growth rate (CAGR) of 8.21%, reflecting modest expansion in core earnings. Cash and cash equivalents at ₹1,547.65 crores are at a low point, and the debtors turnover ratio of 4.49 times indicates some pressure on receivables management.

However, the company remains net-debt free, a significant positive in the pharmaceutical sector where capital structure can be a concern. Management efficiency is high, as evidenced by a strong ROE of 16.90%, underscoring effective utilisation of shareholder funds. Institutional holdings are robust at 31.55%, signalling confidence from sophisticated investors who typically conduct thorough fundamental analysis.

Year-to-date, the stock has declined by 2.72%, but this compares favourably to the Sensex’s 9.33% drop, highlighting relative resilience. Over longer horizons, Alkem has delivered impressive returns: 5.85% over one year, 54.11% over three years, 91.50% over five years, and a remarkable 335.83% over ten years, significantly outperforming the Sensex in each period.

Quality Assessment Reflects Stable Operational Strength

Alkem Laboratories maintains a Mojo Grade of Hold with a score of 50.0, reflecting balanced quality metrics. The company’s operational efficiency and profitability ratios remain solid, though recent flat financial trends temper enthusiasm. The mid-cap classification aligns with its market capitalisation and growth profile, positioning it well within the Pharmaceuticals & Biotechnology sector.

While the company’s growth trajectory has moderated, its strong return ratios and net-debt-free status provide a foundation for stability. The flat quarterly results and low cash reserves warrant caution, but the high institutional ownership and management efficiency support the Hold rating rather than a downgrade.

Comparative Performance and Market Context

Alkem Laboratories’ stock performance relative to the broader market and peers provides important context for the rating change. Over the past year, the stock has gained 5.85%, outperforming the Sensex’s decline of 4.02%. Over three and five years, the stock’s returns of 54.11% and 91.50% respectively have more than doubled the Sensex’s 25.13% and 60.13% returns, underscoring the company’s long-term value creation.

Despite recent flat financial results, the company’s valuation and technical improvements suggest a stabilising outlook. Investors should weigh the attractive valuation against the modest growth and flat quarterly performance when considering their positions.

In summary, the upgrade to Hold reflects a balanced view: valuation metrics have become more compelling, technical indicators show signs of stabilisation, and quality fundamentals remain intact despite recent earnings stagnation. This nuanced assessment supports a cautious but optimistic stance on Alkem Laboratories Ltd going forward.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →